Literature DB >> 26544575

No evidence of posttreatment control after early initiation of antiretroviral therapy.

Sara Gianella1, Christy M Anderson, Douglas D Richman, Davey M Smith, Susan J Little.   

Abstract

As part of a retrospective analysis of 616 individuals followed from incident HIV infection for up to 18 years as part of the San Diego Primary Infection Cohort, we found 16 individuals who started antiretroviral therapy (ART) within the first 4 months of infection and subsequently interrupted ART after being virologically suppressed for a median of 1.75 years. No individual maintained sustained virologic control after interruption of ART, even when treatment was started during the earliest stages of HIV infection. Median time to HIV-RNA rebound after ART interruption was 0.9 months (range: 0.2-6.4 months).

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26544575      PMCID： PMC4638137          DOI： 10.1097/QAD.0000000000000816

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  23 in total

1.  Control of HIV despite the discontinuation of antiretroviral therapy.

Authors:  J Lisziewicz; E Rosenberg; J Lieberman; H Jessen; L Lopalco; R Siliciano; B Walker; F Lori
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

2.  Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection.

Authors:  Laurent Hocqueloux; Thierry Prazuck; Véronique Avettand-Fenoel; Alain Lafeuillade; Bernard Cardon; Jean-Paul Viard; Christine Rouzioux
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

3.  Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Authors:  Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

4.  Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

Authors:  Matthew C Strain; Susan J Little; Eric S Daar; Diane V Havlir; Huldrych F Gunthard; Ruby Y Lam; Otto A Daly; Juin Nguyen; Caroline C Ignacio; Celsa A Spina; Douglas D Richman; Joseph K Wong
Journal:  J Infect Dis       Date:  2005-03-29       Impact factor: 5.226

5.  Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.

Authors:  Sara Gianella; Viktor von Wyl; Marek Fischer; Barbara Niederoest; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Andri Rauch; Bernard Hirschel; Pietro Vernazza; Rainer Weber; Beda Joos; Huldrych F Günthard
Journal:  Antivir Ther       Date:  2011

6.  Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial.

Authors:  Bruno Hoen; Isabelle Fournier; Christine Lacabaratz; Marianne Burgard; Isabelle Charreau; Marie-Laure Chaix; Jean-Michel Molina; Jean-Michel Livrozet; Alain Venet; François Raffi; Jean-Pierre Aboulker; Christine Rouzioux
Journal:  J Acquir Immune Defic Syndr       Date:  2005-11-01       Impact factor: 3.731

7.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

8.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

9.  Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.

Authors:  Viktor von Wyl; Sara Gianella; Marek Fischer; Barbara Niederoest; Herbert Kuster; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Andri Rauch; Bernard Hirschel; Pietro Vernazza; Rainer Weber; Beda Joos; Huldrych F Günthard
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

10.  Limited durability of viral control following treated acute HIV infection.

Authors:  Daniel E Kaufmann; Mathias Lichterfeld; Marcus Altfeld; Marylyn M Addo; Mary N Johnston; Paul K Lee; Bradford S Wagner; Elizabeth T Kalife; Daryld Strick; Eric S Rosenberg; Bruce D Walker
Journal:  PLoS Med       Date:  2004-10-26       Impact factor: 11.069
View more
  10 in total

Review 1.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

2.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Authors:  Golnaz Namazi; Jesse M Fajnzylber; Evgenia Aga; Ronald J Bosch; Edward P Acosta; Radwa Sharaf; Wendy Hartogensis; Jeffrey M Jacobson; Elizabeth Connick; Paul Volberding; Daniel Skiest; David Margolis; Michael C Sneller; Susan J Little; Sara Gianella; Davey M Smith; Daniel R Kuritzkes; Roy M Gulick; John W Mellors; Vikram Mehraj; Rajesh T Gandhi; Ronald Mitsuyasu; Robert T Schooley; Keith Henry; Pablo Tebas; Steven G Deeks; Tae-Wook Chun; Ann C Collier; Jean-Pierre Routy; Frederick M Hecht; Bruce D Walker; Jonathan Z Li
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

3.  Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.

Authors:  Dalton Wamalwa; Sarah Benki-Nugent; Agnes Langat; Kenneth Tapia; Evelyn Ngugi; Helen Moraa; Elizabeth Maleche-Obimbo; Vincent Otieno; Irene Inwani; Barbra A Richardson; Bhavna Chohan; Julie Overbaugh; Grace C John-Stewart
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

4.  Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy.

Authors:  Matthew J Perkins; William P Bradley; Tahaniyat Lalani; Brian K Agan; Timothy J Whitman; Tomas M Ferguson; Jason F Okulicz; Anuradha Ganesan
Journal:  J Acquir Immune Defic Syndr       Date:  2017-07-01       Impact factor: 3.731

Review 5.  Challenges and Promise of Human Immunodeficiency Virus Remission.

Authors:  Yijia Li; Abbas Mohammadi; Jonathan Z Li
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

6.  Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria.

Authors:  Jesse Fajnzylber; Radwa Sharaf; John N Hutchinson; Evgenia Aga; Ronald J Bosch; Wendy Hartogensis; Jeffrey M Jacobson; Elizabeth Connick; Paul Volberding; Daniel J Skiest; David Margolis; Michael C Sneller; Susan J Little; Roy M Gulick; John W Mellors; Rajesh T Gandhi; Robert T Schooley; Keith Henry; Pablo Tebas; Steve Deeks; Tae-Wook Chun; Ann C Collier; Frederick M Hecht; Jonathan Z Li
Journal:  AIDS       Date:  2021-11-01       Impact factor: 4.632

7.  Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.

Authors:  Sarah Fidler; Ashley D Olson; Heiner C Bucher; Julie Fox; John Thornhill; Charles Morrison; Roberto Muga; Andrew Phillips; John Frater; Kholoud Porter
Journal:  J Acquir Immune Defic Syndr       Date:  2017-02-01       Impact factor: 3.731

Review 8.  Learning From the Exceptions: HIV Remission in Post-treatment Controllers.

Authors:  Behzad Etemad; Elmira Esmaeilzadeh; Jonathan Z Li
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

9.  Predicting Post-treatment HIV Remission: Does Size of the Viral Reservoir Matter?

Authors:  Alexander O Pasternak; Christina K Psomas; Ben Berkhout
Journal:  Front Microbiol       Date:  2021-02-26       Impact factor: 5.640

10.  Altered Memory Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection.

Authors:  Roshell Muir; Talibah Metcalf; Virginie Tardif; Hiroshi Takata; Nittaya Phanuphak; Eugene Kroon; Donn J Colby; Rapee Trichavaroj; Victor Valcour; Merlin L Robb; Nelson L Michael; Jintanat Ananworanich; Lydie Trautmann; Elias K Haddad
Journal:  PLoS Pathog       Date:  2016-07-27       Impact factor: 6.823
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.